FDA lab testing found benzene, a cancer-causing impurity, at about 6 ppm in David Cosmetic's CALA hand sanitizer, making it adulterated.
What happened
FDA tested a batch of CALA Advanced Hand Sanitizer Moisturizing with Aloe Vera Extract made at David Cosmetic's Incheon, Korea facility and found in U.S. distribution that it contained benzene at about 6 parts per million. On a December 27, 2021 call, the company committed to recalling that batch but had not started the recall by the date of this letter, and it told FDA it does not test its ingredients or finished hand sanitizer for impurities such as benzene. FDA publicly posted the unacceptable results on January 12, 2022 and placed all of the firm's drugs on Import Alert 66-78 on March 10, 2022.
What FDA found
The hand sanitizer contained benzene, a known human carcinogen, at about 6 ppm, which shows the firm's quality assurance is not working under CGMP (current good manufacturing practice, the minimum quality rules for drug makers).
Section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B))The firm has no finished-product specification for benzene, even though benzene contamination is a known risk in making hand sanitizers.
21 CFR 211.160(b)The firm does not test each finished batch of drug product.
21 CFR 211.165The firm told FDA it does not test its active ingredients or finished hand sanitizers for impurities, including benzene.
The firm promised FDA on December 28, 2021 that it would recall the affected batch but had not started the recall as of this letter.
The firm's reply to FDA's December 27, 2021 request for information was incomplete.
What FDA wants
FDA asks the firm to investigate how benzene got into the product, list all raw materials and suppliers, list and reconcile every hand sanitizer batch shipped to the U.S., send complete batch records, and provide methanol, benzene, acetal, acetaldehyde and other test results. The firm must reply in writing within 15 working days, and FDA strongly recommends hiring a qualified CGMP consultant before making drugs for the U.S. again.
Who should pay attention
- brands and retailers selling private-label hand sanitizer made by contract manufacturers
- U.S. importers and distributors of over-the-counter antiseptic products
- cosmetics companies that also make drug products for the U.S. market
This is a summary. Read the original letter on fda.gov.